<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01217307</url>
  </required_header>
  <id_info>
    <org_study_id>GIPS-III 2010B257</org_study_id>
    <nct_id>NCT01217307</nct_id>
  </id_info>
  <brief_title>Metformin to Reduce Heart Failure After Myocardial Infarction</brief_title>
  <acronym>GIPS-III</acronym>
  <official_title>Metabolic Modulation With Metformin to Reduce Heart Failure After Acute Myocardial Infarction: Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III): a Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will evaluate the effect of metformin therapy during 4 months in
      non-diabetic patients following ST-elevation myocardial infarction on left ventricular
      ejection fraction as measured with cardiac magnetic resonance imaging, compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this trial, the investigators will evaluate the effect of metformin therapy following
      ST-elevation myocardial infarction (STEMI) in a total of 380 non-diabetic patients. This
      trial is a randomized, double blind, controlled trial. The intervention, which consist of
      metformin 500mg twice daily or placebo twice daily, will commence within three hours after
      the percutaneous coronary intervention, and will be continued for 4 months. The primary
      endpoint is the difference between the two intervention groups (metformin vs placebo) in left
      ventricular ejection fraction, as measured with magnetic resonance imaging after 4 months.
      The investigators hypothesize that metformin therapy results in a significantly higher
      ejection fraction in this population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Left Ventricular Ejection Fraction</measure>
    <time_frame>4 months</time_frame>
    <description>The primary efficacy parameter of the GIPS-III trial is LVEF measured by cardiac MRI 4 months after randomization, based on an intention-to-treat analysis. It is hypothesized that metformin therapy will result in a higher ejection fraction after 4 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Incidence of a Cardiovascular Event</measure>
    <time_frame>4 months and longterm follow-up</time_frame>
    <description>Cardiovascular events include major cardiac adverse events (MACE; death, recurrent MI, target lesion revascularization), stroke, non-elective hospitalizations for chest pain or heart failure, all recurrent coronary interventions, and internal cardiac defibrillator implantations. Mortality will be divided into cardiac and non-cardiac. Cardiac death will be divided into three categories: heart failure, sudden death and other. A cardiologist will confirm deaths from cardiovascular causes by examining medical records obtained from hospitals and attending physicians or from attending general practitioner if the patient died at home.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Heart Failure and Glycometabolic State</measure>
    <time_frame>4 months and longterm follow-up</time_frame>
    <description>markers of heart failure: neurohormones (e.g. NT-proBNP), renal function (e.g. MDRD); glycometabolic state: e.g. HbA1c.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarct Size and Transmural Extent of Infarction as Measured With Cardiac Magnetic Resonance Imaging</measure>
    <time_frame>4 months after hospitalization</time_frame>
    <description>myocardial infarct size and transmural extent of infarction will be measured using Late Gadolinium Enhancement cardiac magnetic imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Function</measure>
    <time_frame>4 months</time_frame>
    <description>echocardiographic analysis of diastolic function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycometabolic State</measure>
    <time_frame>4 months and long-term follow-up</time_frame>
    <description>measured by oral glucose tolerance testing and Glycated Hemoglobin according to current criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac MRI After 4 Months, Per Protocol Analysis</measure>
    <time_frame>4 months</time_frame>
    <description>A per-protocol analysis, excluding patients diagnosed with new onset diabetes and treated with oral antihyperglycemic agents or insulin prior to cardiac MRI, will be performed as a secondary efficacy parameter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">380</enrollment>
  <condition>ST Elevation Myocardial Infarction (STEMI)</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Heart Failure</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metformin 500mg twice daily during 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice daily during 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500mg twice daily during 4 months</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo twice daily during 4 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The diagnosis acute MI defined by chest pain suggestive for myocardial ischemia for at
             least 30 minutes, the time from onset of the symptoms less than 12 hours before
             hospital admission, and an ECG recording with ST- segment elevation of more than 0.1
             mV in 2 or more leads.

          -  Successful primary PCI (post-procedural TIMI 2/3);

          -  At least one stent sized ≥ 3.0 mm;

          -  Eligible for 3T CMR imaging;

          -  Verbal followed by written informed consent.

        Exclusion Criteria:

          -  rescue PCI after thrombolytic therapy;

          -  need for emergency coronary artery bypass grafting;

          -  creatinin &gt;177 μmol/L measured pre-PCI;

          -  Younger than 18 years;

          -  Mechanical ventilation;

          -  Diabetes;

          -  Prior myocardial infarction;

          -  Contra-indication to metformin (see safety);

          -  The existence of a life-threatening disease with a life-expectancy of less than 6
             months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iwan CC van der Horst, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thorax Centre, University Medical Centre Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2010</study_first_submitted>
  <study_first_submitted_qc>October 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2010</study_first_posted>
  <results_first_submitted>July 31, 2017</results_first_submitted>
  <results_first_submitted_qc>July 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 30, 2018</results_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Chris Lexis</investigator_full_name>
    <investigator_title>Drs.</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>ST elevation myocardial infarction (STEMI)</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>metformin 500mg twice daily during 4 months
Metformin: Metformin 500mg twice daily during 4 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo twice daily during 4 months
Placebo: Placebo twice daily during 4 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="189"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="188"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>metformin 500mg twice daily during 4 months
Metformin: Metformin 500mg twice daily during 4 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo twice daily during 4 months
Placebo: Placebo twice daily during 4 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="191"/>
            <count group_id="B2" value="189"/>
            <count group_id="B3" value="380"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.7" spread="11.8"/>
                    <measurement group_id="B2" value="58.8" spread="11.5"/>
                    <measurement group_id="B3" value="58.8" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Left Ventricular Ejection Fraction</title>
        <description>The primary efficacy parameter of the GIPS-III trial is LVEF measured by cardiac MRI 4 months after randomization, based on an intention-to-treat analysis. It is hypothesized that metformin therapy will result in a higher ejection fraction after 4 months.</description>
        <time_frame>4 months</time_frame>
        <population>patients undergoing primary percutaneous coronary intervention (PCI) for STEMI</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin 500mg twice daily during 4 months
Metformin: Metformin 500mg twice daily during 4 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo twice daily during 4 months
Placebo: Placebo twice daily during 4 months</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Left Ventricular Ejection Fraction</title>
          <description>The primary efficacy parameter of the GIPS-III trial is LVEF measured by cardiac MRI 4 months after randomization, based on an intention-to-treat analysis. It is hypothesized that metformin therapy will result in a higher ejection fraction after 4 months.</description>
          <population>patients undergoing primary percutaneous coronary intervention (PCI) for STEMI</population>
          <units>% of LVEF</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1" lower_limit="51.6" upper_limit="54.6"/>
                    <measurement group_id="O2" value="54.8" lower_limit="53.5" upper_limit="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Incidence of a Cardiovascular Event</title>
        <description>Cardiovascular events include major cardiac adverse events (MACE; death, recurrent MI, target lesion revascularization), stroke, non-elective hospitalizations for chest pain or heart failure, all recurrent coronary interventions, and internal cardiac defibrillator implantations. Mortality will be divided into cardiac and non-cardiac. Cardiac death will be divided into three categories: heart failure, sudden death and other. A cardiologist will confirm deaths from cardiovascular causes by examining medical records obtained from hospitals and attending physicians or from attending general practitioner if the patient died at home.</description>
        <time_frame>4 months and longterm follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Heart Failure and Glycometabolic State</title>
        <description>markers of heart failure: neurohormones (e.g. NT-proBNP), renal function (e.g. MDRD); glycometabolic state: e.g. HbA1c.</description>
        <time_frame>4 months and longterm follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarct Size and Transmural Extent of Infarction as Measured With Cardiac Magnetic Resonance Imaging</title>
        <description>myocardial infarct size and transmural extent of infarction will be measured using Late Gadolinium Enhancement cardiac magnetic imaging</description>
        <time_frame>4 months after hospitalization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Function</title>
        <description>echocardiographic analysis of diastolic function</description>
        <time_frame>4 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycometabolic State</title>
        <description>measured by oral glucose tolerance testing and Glycated Hemoglobin according to current criteria</description>
        <time_frame>4 months and long-term follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac MRI After 4 Months, Per Protocol Analysis</title>
        <description>A per-protocol analysis, excluding patients diagnosed with new onset diabetes and treated with oral antihyperglycemic agents or insulin prior to cardiac MRI, will be performed as a secondary efficacy parameter</description>
        <time_frame>4 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>metformin 500mg twice daily during 4 months
Metformin: Metformin 500mg twice daily during 4 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo twice daily during 4 months
Placebo: Placebo twice daily during 4 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Reinfarction</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="191"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Cardiovascular death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Target lesion revascularization</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Non-target lesion revascularization</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="191"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>CABG</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="191"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Hospitalization for chest pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="191"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. I.C.C. van der Horst</name_or_title>
      <organization>University Medical Center Groningen</organization>
      <email>i.c.c.van.der.horst@umcg.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

